MGMT and glioblastoma: In line with previous findings that MGMT is a major determinant of TMZ resistance in glioblastoma, our study shows that SQ-TMZ nanoparticles significantly downregulate MGMT expression in TMZ-resistant T98G cells, thereby resensitizing them to alkylating therapy.